del Guercio P, Zanetti M, del Guercio M F, Katz D H
J Immunol. 1985 Jun;134(6):3926-33.
Recently, we described a new lymphokine of B cell origin, capable of selectively preventing the differentiation of T suppressor cells from the precursor into the effector stage. As a result, antibody production against various antigens is markedly increased. We termed this lymphokine B cell-derived enhancing factor (BEF). To discern the mechanism(s) by which BEF interferes with the activation of T suppressor cells, experiments were undertaken to explore the effect of BEF on the induction of Fc receptors (FcR). The induction of FcR on T cells has been implicated in the down-regulation of antibody synthesis, and it has been suggested that the expression of FcR for a given immunoglobulin precedes the release of factors with regulatory functions for the corresponding isotype. In the experiments reported here, murine spleen cells were incubated for 24 hr in the presence of IgG1 or IgA monoclonal antibodies, were washed, and the number of FcR gamma 1+ and FcR alpha+ cells were calculated by a rosette assay. The effect of BEF was studied either during the inductive phase or before, i.e., by pretreating the cells with BEF for 18 hr at 37 degrees C before the inductive phase. Our results show that BEF abolishes, in a dose-dependent manner, the expression of isotype-specific FcR in spleen cells when present during the inductive phase, as well as when cells are pretreated with it. In successive experiments, we tested the effect of BEF on the induction of FcR on T cell-enriched or B cell-enriched spleen cells. The results show that BEF is effective in selectively inhibiting FcR expression on T lymphocytes, but not on B lymphocytes, once isolated from the total spleen cell population. These findings provide further insight into the mechanism by which BEF modulates the immune response, and suggest that different mechanisms may be involved in the induction of FcR on T and B lymphocytes, respectively.
最近,我们描述了一种源自B细胞的新型淋巴因子,它能够选择性地阻止抑制性T细胞从前体分化为效应阶段。结果,针对各种抗原的抗体产生显著增加。我们将这种淋巴因子称为B细胞衍生增强因子(BEF)。为了弄清BEF干扰抑制性T细胞激活的机制,我们开展了实验以探究BEF对Fc受体(FcR)诱导的影响。T细胞上FcR的诱导与抗体合成的下调有关,并且有人提出,针对特定免疫球蛋白的FcR表达先于相应同种型具有调节功能的因子释放。在本文报道的实验中,将小鼠脾细胞在IgG1或IgA单克隆抗体存在的情况下孵育24小时,然后洗涤,通过玫瑰花结试验计算FcRγ1 +和FcRα +细胞的数量。在诱导阶段或之前研究BEF的作用,即在诱导阶段之前将细胞用BEF在37℃预处理18小时。我们的结果表明,当在诱导阶段存在时以及用BEF预处理细胞时,BEF均以剂量依赖性方式消除脾细胞中同种型特异性FcR的表达。在后续实验中,我们测试了BEF对富含T细胞或富含B细胞的脾细胞上FcR诱导的影响。结果表明,一旦从整个脾细胞群体中分离出来,BEF可有效选择性抑制T淋巴细胞上FcR的表达,但对B淋巴细胞无效。这些发现进一步深入了解了BEF调节免疫反应的机制,并表明在T和B淋巴细胞上诱导FcR可能分别涉及不同的机制。